FI4025188T3 - Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia - Google Patents
Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia Download PDFInfo
- Publication number
- FI4025188T3 FI4025188T3 FIEP21724652.9T FI21724652T FI4025188T3 FI 4025188 T3 FI4025188 T3 FI 4025188T3 FI 21724652 T FI21724652 T FI 21724652T FI 4025188 T3 FI4025188 T3 FI 4025188T3
- Authority
- FI
- Finland
- Prior art keywords
- suspension
- paliperidone palmitate
- dose
- paliperidone
- palmitate
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title claims 2
- 229960001057 paliperidone Drugs 0.000 title claims 2
- 238000013265 extended release Methods 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 claims 79
- 229960000635 paliperidone palmitate Drugs 0.000 claims 79
- 239000000725 suspension Substances 0.000 claims 78
- 238000012423 maintenance Methods 0.000 claims 22
- 238000000034 method Methods 0.000 claims 11
- 210000003205 muscle Anatomy 0.000 claims 7
- 208000028017 Psychotic disease Diseases 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 210000000852 deltoid muscle Anatomy 0.000 claims 5
- 239000006172 buffering agent Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 208000022610 schizoaffective disease Diseases 0.000 claims 3
- 239000000375 suspending agent Substances 0.000 claims 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 229960002303 citric acid monohydrate Drugs 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 claims 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- 229940102213 injectable suspension Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119405P | 2020-11-30 | 2020-11-30 | |
| PCT/EP2021/062147 WO2022111859A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4025188T3 true FI4025188T3 (fi) | 2024-02-21 |
Family
ID=75888043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21724652.9T FI4025188T3 (fi) | 2020-11-30 | 2021-05-07 | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia |
Country Status (22)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4025188B1 (en) * | 2020-11-30 | 2024-01-10 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| PL4005555T3 (pl) | 2020-11-30 | 2024-09-02 | Janssen Pharmaceutica Nv | Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu |
| SI4025187T1 (sl) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem |
| CN116528836A (zh) | 2020-11-30 | 2023-08-01 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| CN101163702B (zh) | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
| CA2655335C (en) * | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010313290A1 (en) * | 2009-10-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| WO2016157061A1 (en) * | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| DK3744326T3 (da) * | 2015-04-07 | 2024-02-05 | Janssen Pharmaceutica Nv | Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere |
| CN114783258A (zh) | 2015-06-19 | 2022-07-22 | 詹森药业有限公司 | 用于药物施用和混合的系统及用于所述系统的适当技术的训练 |
| US20190183896A1 (en) * | 2017-12-14 | 2019-06-20 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| EP4025188B1 (en) * | 2020-11-30 | 2024-01-10 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
-
2021
- 2021-05-07 EP EP21724652.9A patent/EP4025188B1/en active Active
- 2021-05-07 DK DK21724652.9T patent/DK4025188T3/da active
- 2021-05-07 PL PL21724652.9T patent/PL4025188T3/pl unknown
- 2021-05-07 LT LTEPPCT/EP2021/062147T patent/LT4025188T/lt unknown
- 2021-05-07 TW TW110116515A patent/TWI877363B/zh active
- 2021-05-07 FI FIEP21724652.9T patent/FI4025188T3/fi active
- 2021-05-07 PT PT217246529T patent/PT4025188T/pt unknown
- 2021-05-07 IL IL303253A patent/IL303253A/en unknown
- 2021-05-07 HU HUE21724652A patent/HUE065573T2/hu unknown
- 2021-05-07 TW TW114105894A patent/TWI926646B/zh active
- 2021-05-07 SM SM20240077T patent/SMT202400077T1/it unknown
- 2021-05-07 KR KR1020257011387A patent/KR20250053980A/ko active Pending
- 2021-05-07 ES ES21724652T patent/ES2973583T3/es active Active
- 2021-05-07 JP JP2023532489A patent/JP7792959B2/ja active Active
- 2021-05-07 MX MX2023006366A patent/MX2023006366A/es unknown
- 2021-05-07 WO PCT/EP2021/062147 patent/WO2022111859A1/en not_active Ceased
- 2021-05-07 SI SI202130102T patent/SI4025188T1/sl unknown
- 2021-05-07 EP EP23219765.7A patent/EP4356966A3/en active Pending
- 2021-05-07 AU AU2021386450A patent/AU2021386450B2/en active Active
- 2021-05-07 CA CA3203566A patent/CA3203566A1/en active Pending
- 2021-05-07 US US17/314,330 patent/US11304951B1/en active Active
- 2021-05-07 CN CN202180080433.0A patent/CN116583270A/zh active Pending
- 2021-05-07 KR KR1020237021429A patent/KR102794804B1/ko active Active
- 2021-05-07 HR HRP20240074TT patent/HRP20240074T1/hr unknown
- 2021-05-07 RS RS20240116A patent/RS65178B1/sr unknown
-
2022
- 2022-04-13 US US17/719,686 patent/US20220249495A1/en not_active Abandoned
-
2023
- 2023-05-30 MX MX2024009188A patent/MX2024009188A/es unknown
-
2024
- 2024-06-20 AU AU2024204213A patent/AU2024204213B2/en active Active
-
2025
- 2025-08-06 US US19/291,832 patent/US20260060986A1/en active Pending
- 2025-10-15 JP JP2025173295A patent/JP2026027255A/ja active Pending
-
2026
- 2026-05-12 AU AU2026203613A patent/AU2026203613A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4025187T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| FI4025189T3 (fi) | Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia | |
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| HRP20240074T1 (hr) | Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem | |
| JP2023552329A5 (cg-RX-API-DMAC7.html) | ||
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| JP2023552149A5 (cg-RX-API-DMAC7.html) | ||
| ME02549B (me) | Cns dostava terapeutskih agensa | |
| RU2010141542A (ru) | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций | |
| RU2361593C3 (ru) | Комбинация азеластина и стероидов | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| JP3597333B2 (ja) | 急性鼻炎を処置するための医薬製剤 | |
| IL291556B2 (en) | Methods and compositions for administration of arylsulfatase A to the central nervous system | |
| JP2023551009A5 (cg-RX-API-DMAC7.html) | ||
| JP2012520882A5 (cg-RX-API-DMAC7.html) | ||
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| US20140171389A1 (en) | Methods for treating cancer | |
| HUP0202243A2 (hu) | Ketotiféntartalmú szemészeti készítmény | |
| US20060241037A1 (en) | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| CA2399505A1 (en) | Nasal calcitonin formulations | |
| JP2002537255A (ja) | リウマチ性炎症性プロセスに対する5−ht3レセプターアンタゴニストの全身的使用 | |
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| ES2197781B1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. |